Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

CHMP recommends approval of empagliflozin for type 2 diabetes

March 25, 2014

Washington University School of Medicine to assess EDI-200 in rare genetic disorder

March 25, 2014

Researchers at Amgen disclose novel GKRP/GK interaction inhibitors

March 24, 2014

Adocia reports data for combination of long-acting and fast-acting insulin

March 24, 2014

Researchers identify potential antiobesity drug target, describe potent inhibitor

March 21, 2014

Phase Ia results for HMS-5552 lead to initiation of phase Ib study

March 20, 2014

Isis Pharmaceuticals begins phase I study of ISIS-ANGPTL3Rx to treat hyperlipidemia

March 20, 2014

Bristol-Myers Squibb presents data for BMS-903452

March 20, 2014

Researchers at Merck & Co. design novel AMPK activators for diabetes

March 20, 2014

Dainippon Sumitomo Pharma presents a novel potent and selective 11beta-HSD1 inhibitor

March 19, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...